IFNL2
IFNL2 (interferon lambda 2, also known as IL-28A or IL28A) is a secreted cytokine of the type-III interferon family with antiviral, antitumour and immunomodulatory activities. It acts mainly on epithelial cells, where it helps drive antiviral host defence. Browse Assay Genie's current range of IFNL2 research reagents below, or read on for the biology behind the target.
IFNL2 is a cytokine that plays a critical role in antiviral host defence, predominantly in epithelial tissues. It is a ligand for a heterodimeric class II cytokine receptor made up of IL10RB and IFNLR1. Receptor engagement activates the JAK/STAT signalling pathway, leading to expression of IFN-stimulated genes (ISGs), which mediate the antiviral state. IFNL2 also exerts an immunomodulatory effect by up-regulating MHC class I antigen expression.
The action of IFNL2 is cell type-selective. Its receptor distribution is restricted, and the epithelial cell-specific expression of IFNLR1 means the cytokine is primarily active in epithelial cells. It seems not to be essential for early virus-activated host defence in vaginal infection, but it has an important role in Toll-like receptor (TLR)-induced antiviral defence and a significant role in antiviral immunity in the intestinal epithelium. Expression of the cytokine can be induced by viral infection.
The IFNL2 gene encodes a cytokine distantly related to type I interferons and the IL-10 family, and the protein belongs to the type-III (lambda) interferon family. It was previously named interleukin 28A (IL-28A). The gene forms a cluster on chromosome 19q13 with IFNL3 (IL-28B) and IL-29, three closely related cytokine genes whose products all interact with the IL10RB and IL28RA (IFNLR1) receptor complex.
IFNL2 drives ISG expression through JAK/STAT signalling and contributes to the antiviral state, making it a useful target for studying host defence.
Activity is restricted to epithelial cells by IFNLR1 expression, so IFNL2 is relevant to studies of mucosal and epithelial responses.
IFNL2 plays a significant role in antiviral immune defence in the intestinal epithelium and in TLR-induced antiviral responses.
IFNL2 has antitumour and immunomodulatory activities, including up-regulation of MHC class I antigen expression.
IFNL2 is a secreted cytokine that binds the IL10RB/IFNLR1 receptor complex and activates JAK/STAT signalling, inducing IFN-stimulated genes that establish an antiviral state. It acts mainly on epithelial cells and also up-regulates MHC class I antigen expression.
IFNL2 is also known as IL-28A or IL28A, and was previously named interleukin 28A. It belongs to the type-III or lambda interferon family, alongside IFNL3 (IL-28B) and IL-29, which are encoded by neighbouring genes.
A mouse ortholog, Ifnl2, is recorded for this gene. IFNL2 is encoded in a cluster of three related cytokine genes in humans. Check the datasheet of any product for its validated reactivity.
Other type-III interferon family members and lambda interferon targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q8IZJ0; product specifications from Assay Genie datasheets.